Ivabradina Eg (Ivabradine Hydrochloride)

Ivabradine is used to manage cardiovascular conditions where heart‑rate reduction improves outcomes.

• Chronic stable angina pectoris: reduces frequency of angina attacks and improves exercise tolerance.
• Heart failure with reduced ejection fraction: lowers heart rate, alleviating symptoms and supporting cardiac function.

• Ivabradine selectively binds to the hyperpolarization‑activated cyclic nucleotide‑gated (HCN) channels that generate the If current in sino‑atrial node pacemaker cells. By inhibiting this inward mixed Na⁺/K⁺ current, the drug slows spontaneous depolarization, decreasing the heart rate without compromising myocardial contractility or ventricular repolarisation. The effect is dose‑dependent and reversible, allowing heart‑rate control while preserving blood pressure and cardiac output. Ivabradine does not interact with beta‑adrenergic receptors, distinguishing it from beta‑blockers.

Ivabradine may be associated with several adverse reactions, ranging from frequent, mild events to rare, serious conditions.

Common Side Effects

• Bradycardia: slower than intended heart rate.
• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Symptomatic bradycardia: may cause syncope or hypotension.
• Atrial fibrillation: irregular heart rhythm.
• Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing ivabradine, clinicians should consider several precautionary measures to ensure patient safety.

• Cardiac monitoring: assess resting heart rate before initiation and periodically during therapy.
• Concomitant beta‑blockers: avoid excessive heart‑rate lowering by adjusting doses.
• Severe hepatic impairment: use with caution as metabolism may be reduced.
• Pregnancy and lactation: contraindicated unless benefits outweigh potential risks.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine can interact with other medicines, influencing its plasma concentration or combined physiological effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine levels.
• Concomitant diltiazem or verapamil: can cause pronounced bradycardia.
• Other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may require dose adjustment.
• QT‑prolonging drugs: monitor ECG for interval changes.
• Hypotensive agents: observe for additive blood pressure reduction.